Shares of 10x Genomics Inc (TXG, Financial) surged 4.91% in mid-day trading on Oct 11. The stock reached an intraday high of $16.48, before settling at $16.44, up from its previous close of $15.67. This places TXG 71.61% below its 52-week high of $57.90 and 17.26% above its 52-week low of $14.02. Trading volume was 1,456,978 shares, 103.1% of the average daily volume of 1,412,658.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for 10x Genomics Inc (TXG, Financial) is $25.64 with a high estimate of $46.00 and a low estimate of $16.00. The average target implies an upside of 55.98% from the current price of $16.44. More detailed estimate data can be found on the 10x Genomics Inc (TXG) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, 10x Genomics Inc's (TXG, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 10x Genomics Inc (TXG, Financial) in one year is $58.88, suggesting a upside of 258.15% from the current price of $16.44. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 10x Genomics Inc (TXG) Summary page.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
